Breaking news

Google To Integrate Ads Into AI-Powered Search Overviews

Google has announced plans to incorporate search and shopping ads within its AI-generated answers, marking a significant expansion of its advertising capabilities. This initiative, which will be tested in the United States, follows the introduction of the AI Overviews feature at Google’s recent I/O conference. The ads will appear in a ‘sponsored’ section, tailored to the relevance of the user’s query.

Strategic Expansion in AI and Advertising

This move underscores Google’s strategy to leverage its dominance in traditional search advertising by integrating advanced generative AI technologies. The initiative aims to boost ad sales, a major revenue source, which saw a 13% increase to $61.7 billion in Q1 2024. By embedding ads within AI-generated search results, Google seeks to maintain its competitive edge and revenue growth amidst evolving digital landscapes.

Ongoing Developments and Future Directions

Google will continue refining new ad formats, drawing on feedback from advertisers. Enhancements showcased at the I/O conference, including updates to the Gemini chatbot and search engine improvements, highlight Google’s commitment to advancing AI across its services.

Google’s integration of ads into AI-driven search overviews represents a forward-thinking approach to digital advertising. As the company navigates the intersection of AI innovation and commercial strategy, these developments are set to influence the broader advertising ecosystem significantly.

Medochemie And Theramir Announce Strategic Investment Agreement To Advance Biotech Manufacturing In Cyprus

Pharmaceutical manufacturer Medochemie and biotechnology company Theramir, both Cyprus-based, have announced a strategic investment agreement and collaboration aimed at developing next-generation biological therapies and expanding manufacturing capabilities in Cyprus.

The agreement, announced on 2 September 2026, brings together Medochemie’s experience in pharmaceutical manufacturing and Theramir’s biotechnology research. The companies said the collaboration would support advanced pharmaceutical manufacturing in Cyprus and south-eastern Europe.

What The Partnership Covers

Medochemie’s contribution will include its expertise in manufacturing sterile therapeutic products and its access to international markets.

Theramir develops technologies based on extracellular vesicles and microRNAs. Its work includes using stem-cell-derived extracellular vesicles to deliver microRNAs, small, non-coding RNA molecules that regulate genes and biological pathways associated with cancer growth and metastasis.

Under the agreement, the companies will jointly support the development of “Good Manufacturing Practice” capabilities for next-generation biological therapies. The partnership is also intended to help move these therapies towards clinical development.

A Wider Role For Cyprus

The collaboration will also support Theramir’s wider research programme. According to the companies, it is intended to strengthen Cyprus’s biotechnology infrastructure and expand local capacity in next-generation biomanufacturing.

They present the agreement as a step towards giving Cyprus a larger role in biotechnology and advanced pharmaceutical manufacturing for south-eastern Europe and international markets.

The Future Forbes Realty Global Properties
Aretilaw firm
Uol
eCredo

Become a Speaker

Become a Speaker

Become a Partner

Subscribe for our weekly newsletter